Use of a home-use test to diagnose HIV infection in a sex partner: a case report
© Katz et al.; licensee BioMed Central Ltd. 2012
Received: 6 June 2012
Accepted: 14 August 2012
Published: 15 August 2012
Home-use HIV tests have the potential to increase testing and may be used by sex partners to inform sexual decision-making. To our knowledge, this is the first report of an individual diagnosed with HIV using a home-use test with a sex partner.
We are conducting a randomized controlled trial of home self-testing for HIV using the OraQuick ADVANCE® HIV-1/2 Antibody Test on oral fluids. In 2011, a 27-year-old, homeless, Latino man who has sex with men not enrolled in the trial (the case) reported receiving a reactive result from a diverted study kit. When interviewed by study staff, the case reported that, 11 months prior, he had unprotected anal sex with a trial subject without discussing HIV status. Afterwards, the subject asked the case if he would like to test, performed the test, and disclosed the reactive result. The case reported altering his behavior to decrease the risk of HIV transmission to subsequent partners and sought care two months later.
This case demonstrates that home-use HIV tests will be used by sex partners to learn and disclose HIV status and inform sexual decision-making. It also highlights concerns regarding the absence of counseling and the potential for delayed entry into HIV care. Additional research must be done to determine under what circumstances home-use tests can be used to increase awareness of HIV status, how they impact linkage to care among persons newly diagnosed with HIV, and whether they can be safely used to increase the accuracy of serosorting.
KeywordsHIV screening Home-use tests Men who have sex with men Serosorting Rapid HIV testing
HIV testing is not only the entry point into care for HIV-infected individuals but also an effective prevention intervention because most newly-diagnosed individuals will alter their behavior to decrease transmission to others and antiretroviral therapy can reduce infectiousness.
In 1996, the U.S. Food and Drug Administration (FDA) approved the Home Access HIV-1 Test System (Home Access Health Corporation; Hoffman Estates, IL), a home collection kit for HIV antibody testing. With home collection, testers send self-collected dried blood spots to a laboratory and learn their test results by phone. In the first year it was available, 174,316 kits were sold and 0.9% persons were positive, 49% of whom had never tested before. Few have used these kits, however, in part due to concerns about accuracy and cost[3–5].
Home-use tests, through which testers use a rapid HIV test on self-collected oral fluids or blood to learn their HIV status at home, have been posited as an alternative method to increase HIV testing[6–8] and thereby decrease the time HIV-infected individuals are unaware of their status and potential for transmission. However, there are concerns about the potential for misinterpretation of test results, greater number of false-negative test results during the relatively long window period of currently available rapid tests, reduced access to risk-reduction counseling, decreased screening for sexually transmitted infections (STIs), missed opportunities to link HIV-infected persons into care or to perform partner services, and reduced accuracy of HIV surveillance[7–10]. When home-use tests are available over-the-counter, they may also be used by sex partners to inform sexual decision-making.
In July 2012, the FDA approved the first over-the-counter home-use HIV test, the OraQuick® In-Home HIV Test (OraSure Technologies, Inc., Bethlehem, PA). In premarketing studies of untrained users in uncontrolled settings, the test was 93.0% sensitive, 99.98% specific, and had a window period of 3 months. No industry-sponsored studies were planned to address whether at-risk individuals will be more likely to test or to test more often if home-use tests are available; concerns regarding reductions in counseling, linkage to care, and accuracy of surveillance; or home testing by sex partners.
The iTest Study is an ongoing, NIH-funded, randomized controlled trial to evaluate the impact of access to home-use tests on HIV testing frequency. HIV-negative men who have sex with men (MSM) are randomized to home self-testing using the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (which uses the same technology as the approved home-use test) on oral fluids or to standard HIV testing for 15 months (Clinicaltrials.gov Identifier NCT01161446). Participants randomized to home self-testing are trained to use the test at enrollment and receive one test kit at a time for use on themselves only. Study test kits include the test and study-specific instructions, counseling materials, and local resources and are provided at no cost to participants.
We report the diversion of a study test kit to test a trial subject’s sex partner, whose rapid HIV test on oral fluids was reactive. To our knowledge, this is the first report of an individual diagnosed with HIV using a home-use test with a sex partner.
In 2011, a 27-year-old, homeless, gay-identified Latino MSM not enrolled in the trial (the case) was seen at the Public Heath – Seattle & King County (PHSKC) STD Clinic and reported receiving a reactive result from a diverted study kit. This case study received ethical approval from the University of Washington Institutional Review Board, and written informed consent was obtained from the case for a semi-structured interview about his experience testing with a sex partner and subsequent entry into care.
The case reported that, 11 months prior to this interview, he had unprotected anal sex and used methamphetamine with a trial subject without discussing HIV status. Afterwards, the trial subject asked the case if he wanted to use a study test kit. The case last tested 13 months earlier. The trial subject collected the case’s oral fluid sample, performed the test, and disclosed the reactive result. The case thought it was an acceptable way to learn his HIV status. The case and trial subject did not engage in further sexual activity. Neither confirmatory testing nor post-exposure prophylaxis was discussed.
The case did not seek confirmatory testing immediately. He assumed the results were definitive and did not want antiretroviral therapy. He reported being subsequently more likely to disclose his HIV status and use condoms with sex partners. Two months later, he sought confirmatory testing at the PHSKC STD Clinic. He initiated HIV care two months after confirmatory testing. Six months after the home test, his CD4+ T-cell count was 396 cells/mL, and his HIV RNA level was 15,080 copies/mL. One year after the home test, he was engaged in HIV care but not receiving antiretroviral therapy.
This case highlights potential benefits and risks of home-use HIV tests. First, home-use tests have the potential to increase testing due to convenience, anonymity, and reduced time needed to test[6–8]. Furthermore, the test result obtained by the trial subject was accurate, the newly-diagnosed case felt comfortable receiving his result from a partner in a nonmedical setting, and the case altered his behavior to reduce ongoing HIV transmission despite the absence of post-test counseling. On the other hand, although the case received the correct preliminary result, he was unaware that he needed confirmatory testing and delayed seeking care. The absence of post-test counseling also meant that the trial subject, whose identity remains unknown to us, was unaware of the availability of and recommendation for post-exposure prophylaxis.
Although in this case the partners had already engaged in unprotected sex, partners may choose to test together to inform sexual decision-making. Many MSM serosort (i.e. choose to have sex only with partners of concordant HIV status, to use condoms only with discordant partners, or to have HIV-negative partners be the insertive partner in discordant partnerships) based on what partners disclose directly or indirectly. If MSM trust the results of home-use tests and are therefore more likely to serosort, the ability for sex partners to test at home could increase unprotected sex and allow for transmission of other STIs. OraQuick’s relatively long window period could also increase false-negative results during primary infection and lead to unprotected sex when individuals are most infectious. However, the results of home-use tests may be more accurate than self-reported HIV status and may therefore decrease unprotected sex between serodiscordant partners. Another concern is that the availability of home-use tests may result in coerced testing or intimate partner violence, particularly if partnerships are newly identified as serodiscordant.
This case report relied on an interview with the case and therefore may be limited by recall error and social desirability bias.
This case demonstrates that home-use tests can be used to successfully identify HIV infection and that they will likely be used by MSM to test sex partners. This case also highlights concerns about the absence of post-test counseling and the potential for delayed linkage to care among those who receive reactive home-use tests. The U.S. National HIV/AIDS Strategy emphasizes immediate linkage to care because delaying care can adversely impact the HIV-infected individual’s health and ongoing transmission. Additional research must be done to determine under what circumstances home-use tests can be used to increase awareness of HIV status, how they impact linkage to care among persons newly diagnosed with HIV, and whether home-use tests can be safely used to increase the accuracy of serosorting.
Written informed was obtained from the case for publication of this Case report. A copy of the written consent is available for review by the Series Editor of this journal.
Men who have Sex with Men
Sexually Transmitted Infections
Food and Drug Administration.
This work was funded by the National Institutes of Health (grant number R01 MH086360). The funding source had no role in the design and conduct of the study; data collection, analysis, and interpretation; the writing of this manuscript; and the decision to submit the manuscript for publication. This research was supported by the University of Washington Center for AIDS Research (CFAR), an NIH funded program (P30 AI027757) which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA).
- Marks G, Crepaz N, Senterfitt JW, Janssen RS: Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005, 39 (4): 446-453. 10.1097/01.qai.0000151079.33935.79.PubMedView ArticleGoogle Scholar
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011, 365 (6): 493-505. 10.1056/NEJMoa1105243.PubMedPubMed CentralView ArticleGoogle Scholar
- Branson BM: Home sample collection tests for HIV infection. JAMA. 1998, 280 (19): 1699-1701. 10.1001/jama.280.19.1699.PubMedView ArticleGoogle Scholar
- Colfax GN, Lehman JS, Bindman AB, Vittinghoff E, Vranizan K, Fleming PL, Chesney M, Osmond D, Hecht FM: What happened to home HIV test collection kits? Intent to use kits, actual use, and barriers to use among persons at risk for HIV infection. AIDS Care. 2002, 14 (5): 675-682. 10.1080/0954012021000005533a.PubMedView ArticleGoogle Scholar
- Spielberg F, Critchlow C, Vittinghoff E, Coletti AS, Sheppard H, Mayer KH, Metzgerg D, Judson FN, Buchbinder S, Chesney M, et al: Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study Group. AIDS. 2000, 14 (12): 1819-1828. 10.1097/00002030-200008180-00018.PubMedView ArticleGoogle Scholar
- Spielberg F, Levine RO, Weaver M: Self-testing for HIV: a new option for HIV prevention?. Lancet Infect Dis. 2004, 4 (10): 640-646. 10.1016/S1473-3099(04)01150-8.PubMedView ArticleGoogle Scholar
- U.S. Food and Drug Administration: Blood Products Advisory Committee Meeting Issue Summary. 2012, Available at:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM303657.pdf. Accessed 18 May 2012,Google Scholar
- Campbell S, Klein R: Home testing to detect human immunodeficiency virus: boon or bane?. J Clin Microbiol. 2006, 44 (10): 3473-3476. 10.1128/JCM.01511-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Walensky RP, Bassett IV: HIV self-testing and the missing linkage. PLoS Med. 2011, 8 (10): e1001101-10.1371/journal.pmed.1001101.PubMedPubMed CentralView ArticleGoogle Scholar
- Walensky RP, Paltiel AD: Rapid HIV testing at home: does it solve a problem or create one?. Ann Intern Med. 2006, 145 (6): 459-462.PubMedView ArticleGoogle Scholar
- Carballo-Dieguez A, Frasca T, Dolezal C, Balan I: Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. J Sex Res. 2012, 49 (4): 379-387. 10.1080/00224499.2011.647117.PubMedPubMed CentralView ArticleGoogle Scholar
- Health Resources and Services Administration: The HIV/AIDS Bureau HIV Core Clinical Performance Measures for Adult/Adolescent Clients: Group 1. 2011, Available at:ftp://ftp.hrsa.gov/hab/habGrp1PMs08.pdf. Accessed 1 December 2011.,Google Scholar
- Eaton LA, Kalichman SC, O'Connell DA, Karchner WD: A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission. AIDS Care. 2009, 21 (10): 1279-1288. 10.1080/09540120902803208.PubMedPubMed CentralView ArticleGoogle Scholar
- Stekler JD, Swenson PD, Coombs RW, Dragavon J, Thomas KK, Brennan CA, Devare SG, Wood RW, Golden MR: HIV testing in a high-incidence population: is antibody testing alone good enough?. Clin Infect Dis. 2009, 49 (3): 444-453. 10.1086/600043.PubMedPubMed CentralView ArticleGoogle Scholar
- Carballo-Dieguez A, Balan I, Frasca T, Dolezal C, Valladares J: Use of a rapid HIV home test to screen potential sexual partners prevents HIV exposure in a high-risk sample of MSM [abstract]. XIX International AIDS Conference. 2012, Washington, DC: International AIDS Society, 22–27 JulyGoogle Scholar
- White House Office of National AIDS Policy: National HIV/AIDS Strategy for the United States. 2011, Available at:http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf. Accessed 1 December,Google Scholar
- Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, et al: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009, 360 (18): 1815-1826. 10.1056/NEJMoa0807252.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.